The biotech firm reported a Q2 GAAP loss of $0.63 per share and held $136.2 million in cash as of June 30, 2026.
ImageneBio, Inc. reported a second-quarter GAAP loss of $0.63 per share, reflecting ongoing investment in its pipeline. The company’s cash position stood at $136.2 million at the end of the period, bolstered by a $30 million PIPE financing in April 2026.
The cash balance is expected to support operations beyond the near term, though the company did not specify a timeline. Prior quarters showed similar losses as ImageneBio advances its clinical programs.
No immediate market reaction was disclosed in the release.